Sign In
Buy BLFS
$34.64
-0.0200 (-0.0577%)
At Close: Aug 10, 2026
4 Medical Product Stocks to Watch From a Challenging Industry
10:21am, Monday, 17'th Nov 2025
The Zacks Medical products industry sees steady demand, but macro headwinds keep growth under pressure in 2025. BSX, PODD, BLFS and ALUR reflect the favorable fundamentals.
BioLife Solutions to Participate in Upcoming Investor Conferences in November and December 2025
07:15am, Monday, 17'th Nov 2025
BOTHELL, Wash. , Nov. 17, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) mar
New Strong Buy Stocks for November 10th
07:16am, Monday, 10'th Nov 2025
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
BioLife Solutions, Inc. (BLFS) Q3 2025 Earnings Call Transcript
11:06pm, Thursday, 06'th Nov 2025
BioLife Solutions, Inc. ( BLFS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Troy Wichterman - Chief Financial Officer Roderick de Greef - CEO & Chairman Conference Call Pa
BioLife Solutions, Inc. (BLFS) Surpasses Q3 Earnings and Revenue Estimates
06:36pm, Thursday, 06'th Nov 2025
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.02 per share a year
BioLife Solutions Reports Third Quarter 2025 Financial Results
04:03pm, Thursday, 06'th Nov 2025
Cell Processing revenue of $25.4 million, up 33% over Q3 2024 GAAP gross margin of 62% and non-GAAP adjusted gross margin of 64% GAAP net income of $0.6 million and non-GAAP adjusted EBITDA of $7.8
BioLife Solutions to Report Third Quarter 2025 Financial Results and Business Update on November 6, 2025
04:03pm, Thursday, 23'rd Oct 2025
BOTHELL, Wash. , Oct. 23, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") m
BioLife Solutions Announces the Sale of its evo Cold Chain Logistics Subsidiary
08:04am, Tuesday, 07'th Oct 2025
BOTHELL, Wash. , Oct. 7, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools for the cell and gene the
BioLife: Back To Basics Is Getting Traction (Rating Upgrade)
09:43am, Wednesday, 01'st Oct 2025
After multiple acquisitions and significant dilution of shareholders, BioLife shed two freezer businesses which it couldn't get going. Focusing mostly on its core biopreservation media business is put
Does BioLife Solutions (BLFS) Have the Potential to Rally 25.6% as Wall Street Analysts Expect?
10:56am, Friday, 29'th Aug 2025
The consensus price target hints at a 25.6% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
4 Medical Product Stocks to Watch From a Challenging Industry
09:36am, Thursday, 14'th Aug 2025
The Zacks Medical products industry sees steady demand, but tariffs & policy headwinds keep growth under pressure in 2025. NVST, BLFS, INFU and MRMD reflect the favorable fundamentals.
BioLife Solutions (BLFS) Upgraded to Strong Buy: Here's Why
01:01pm, Tuesday, 12'th Aug 2025
BioLife Solutions (BLFS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 39.92% Upside in BioLife Solutions (BLFS): Here's What You Should Know
10:55am, Tuesday, 12'th Aug 2025
The mean of analysts' price targets for BioLife Solutions (BLFS) points to a 39.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amon
BioLife Solutions, Inc. (BLFS) Q2 2025 Earnings Call Transcript
03:22pm, Friday, 08'th Aug 2025
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Roderick de Greef - CEO & Chairman Troy Wichterman - Chief Financial Officer Conf
BioLife Solutions, Inc. (BLFS) Reports Break-Even Earnings for Q2
06:21pm, Thursday, 07'th Aug 2025
BioLife Solutions, Inc. (BLFS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.06 per share a year ago.
